TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Cohort A~  1. Patient has provided written informed consent.~* Cohort B~  1. Need for long-term oral anticoagulation;~ 2. Patient has provided written informed consent.~Exclusion Criteria:~* Cohort A~  1. Need for long-term oral anticoagulation;~ 2. Drug-eluting stent implantation within 3 months prior to TAVI procedure;~ 3. Bare-metal stent implantation within 1 month prior to TAVI procedure;~ 4. Allergy or intolerance to aspirin or clopidogrel.~* Cohort B~  1. Drug-eluting stent implantation within 3 months prior to TAVI procedure;~ 2. Bare-metal stent implantation within 1 month prior to TAVI procedure;~ 3. Allergy or intolerance to (N)OAC or clopidogrel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin + Clopicogrel (Cohort A) (Type: ACTIVE_COMPARATOR): Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
- Aspirin monotherapy (Cohort A) (Type: ACTIVE_COMPARATOR): Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
- OAC + Clopicogrel (Cohort B) (Type: ACTIVE_COMPARATOR): Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
- OAC monotherapy (Cohort B) (Type: ACTIVE_COMPARATOR): Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participating in the ACCORD study~Exclusion Criteria:~* Has had laser photocoagulation for DR~* Has had vitrectomy surgery for DR

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Intensive glycemia control (Type: EXPERIMENTAL): A strategy of intensive glycemia treatment to HbA1c less than 6%
- Standard glycemia control (Type: ACTIVE_COMPARATOR): A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
- Intensive BP control (Type: EXPERIMENTAL): A strategy of BP treatment for SBP less than 120 mm Hg
- Standard BP control (Type: ACTIVE_COMPARATOR): A strategy of BP treatment for SBP less than 140 mm Hg
- Fibrate (Type: EXPERIMENTAL): Blinded fenofibrate + simvastatin 20-40 mg/d
- Fibrate Placebo (Type: PLACEBO_COMPARATOR): Blinded placebo + simvastatin 20-40 mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Only anti-TNF naïve patients will be included in this study~* Patients between 18 to 80 years of age~* Patients due to start treatment with anti-TNF blocking agents - etanercept or adalimumab~Patients with rheumatoid arthritis~* Only patients meeting the 1987 American College of Rheumatology (ACR) revised classification criteria for rheumatoid arthritis will be included~* Patients should have active rheumatoid arthritis, defined by an initial DAS28 score \>5.1~* Patients should have at least 1 joint suitable for synovial biopsy~* Patients can be on concurrent DMARDs but they should have been on a stable dose of DMARD for at least 1 month prior to study entry~* Patients can be on a concurrent dose of glucocorticoids (up to 10mg daily) and they should have been on a stable dose for at least 4 weeks prior to study entry~Patients with psoriatic arthritis~* Patients should have a secure diagnosis of psoriatic arthritis determined by a rheumatologist~* Patients with psoriatic arthritis included in this study should have evidence of concurrent psoriatic skin lesions at the time of study entry~* Patients should have at least one joint suitable for synovial biopsy~* Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at least 1 month prior to study entry~Patients with Ankylosing spondylitis~* Patient should fulfil the Modified New York Criteria for diagnosis of ankylosing spondylitis~* Patients can be on concurrent NSAIDs~* Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at least 1 month prior to study entry~Exclusion Criteria:~* Patients who have been previously treated with anti-TNF therapy for whatever reason~* Patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who do not fulfil the diagnostic criteria for these conditions as above~* Patient who have received an intra-articular injection of steroids or have received an intra-muscular injection of depot steroid to treat disease flare in the preceding 4 weeks prior to commencing anti-TNF therapy.~* Patients with intercurrent, active infection of any type, excluding the common cold

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rheumatoid arthritis (Type: None): Participants with Rheumatoid arthritis
- Ankylosing spondylitis (Type: None): Participants with Ankylosing spondylitis
- Psoriatic arthritis (Type: None): Participants with Psoriatic arthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female in good general health~* Must have presbyopia~Exclusion Criteria:~* History of allergic reaction to the study drug or any of its components~* Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- BRIMOCHOL™ PF (Type: EXPERIMENTAL): A single drop in each eye at a visit.
- Carbachol PF (Type: ACTIVE_COMPARATOR): A single drop in each eye at a visit.
- Brimonidine tartrate (Type: ACTIVE_COMPARATOR): A single drop in each eye at a visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female who is at least 18 years of age or older.~2. A clinical diagnosis of facial rosacea.~3. A Clinician Erythema Assessment (CEA) score of greater than or equal to 3 at Screening and at Baseline/Day 1 (prior to the study drug application).~4. A Patient Self Assessment (PSA) score of greater than or equal to 3 at Screening and at Baseline/Day 1 (prior to the study drug application).~Key Exclusion Criteria:~1. Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.~2. Presence of three (3) or more facial inflammatory lesions of rosacea.~3. Current treatment with monoamine oxidase (MAO) inhibitors, barbiturates, opiates, sedatives, systemic anesthetics, or alpha agonists.~4. Less than 3 months stable dose treatment with tricyclic antidepressants, cardiac glycosides, beta blockers or other antihypertensive agents.~5. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD07805/47 gel (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 5 years~* The subject has severe or moderately severe hemophilia A defined by a baseline factor VIII level \<= 2% of normal documented at screening or historically (e.g., at hemophilia diagnosis)~* Subjects may enroll regardless of their serologic status for human immunodeficiency virus (HIV-1) and hepatitis C virus (HCV)~* The subject requires a surgical, dental or other invasive procedure--either elective or emergency~* The subject has a history of at least 150 exposure days for all other factor VIII products (as estimated by the study site investigator) prior to study entry~* The subject has a life expectancy of at least 28 days from the day of surgery~* The subject has been informed of the nature of the study, agreed to its provisions, and signed and dated the informed consent form approved by the appropriate IRB/IEC and Baxter BioScience~Exclusion Criteria:~* The subject has a detectable inhibitor to factor VIII in the local hemostasis laboratory at the investigative site at the time of enrollment~* The subject has a history of inhibitor to factor VIII \> 1.0 BU. Note: If the subject has a history of an inhibitor titer \> 1.0 BU at any time prior to enrollment but demonstrated expected clinical responses to conventional doses of factor VIII therapy, the subject may enroll~* The subject has known hypersensitivity to Recombinate~* The subject is currently participating in another investigational drug study, or has participated in any clinical trial involving an investigational drug within 30 days of study entry~* The subject has clinical and/or laboratory evidence of abnormal hemostasis from causes other than hemophilia A (e.g., late-stage chronic liver disease, immune thrombocytopenic purpura, disseminated intravascular coagulation)~* The subject is identified by the investigator as being unable or unwilling to cooperate with study procedures.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ankle brachial index of \<0.9 in at least one leg~* History of intermittent claudication (unilateral or bilateral)~* A stable medication regimen for at least 6 months~Exclusion Criteria:~* Limiting coronary artery disease~* Renal failure (serum creatinine \> 0.20 mmol/L)~* Current treatment or treatment within the previous 6 months with ACE inhibitors or angiotensin II receptor antagonists

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male (or transgender male person at birth)~* At least 18 years old~* HIV-seronegative~* Having had at least one anal sex episode with another man within the previous 6 months~* Having at least one of the following criteria:~  * Have a sexual partner (male or female) infected with HIV without evidence of virological suppression~ * Have had anal or vaginal sex episodes without condoms with more than one partner within the previous 6 months~ * Have had a sexually-transmitted infection (STI) within the previous 6 months (syndromic or biological approach, or mentioned by the participant)~ * Have received post-exposure prophylaxis for HIV within the previous 6 months~ * Wishing to reinforce its means of prevention through the use of PrEP~* Accepting to participate in the study and signing the informed consent form~Exclusion Criteria:~* Clinical manifestations suggesting a primary HIV infection~* Recent probable HIV exposure~* Creatinine clearance \<60 mL/min calculated according to the Cockroft \& Gault formula~* Positive or undetermined HBsAg~* Allergy or contraindication to any of the components of PrEP~* Participation in another biomedical and/or behavioral study on HIV or STIs (excluding CohMSM)~* Disability of the person making it difficult, if not impossible, to participate in the study or understanding of the information given to him~* Predictable non-compliance with the protocol (geographical distance, non-compliance with monitoring or other reasons)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HIV prevention package including PrEP (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Nulliparous women.~  * cervical dilatation in the active phase of less than 1.2 cm/h for nulliparous women~ * Gestational age ≥ 37 weeks.~ * Singleton pregnancy.~ * Vertex presentation.~ * Cervical dilatation ≥ 4cm.~ * No evidence of maternal or fetal distress.~ * Average size baby.~Exclusion Criteria:~* History of cervical surgery.~* Mal-presentation and mal-positions.~* Hypersensitivity to Hyoscine.~* Contraindication for vaginal delivery.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Hyoscine group (Type: ACTIVE_COMPARATOR): 7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
- Control group (Type: PLACEBO_COMPARATOR): Group B, will receive 2 ml of normal saline single intravenous dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of TEAS on the Quality of Early Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective gynecological laparoscopic surgery.~* ASA physical status of I-II.~* Ages ranged from 29-60 yr.~Exclusion Criteria:~* Recent use of TEAS or acupuncture.~* Neural damage or infection along the meridian at which the acupoints lay.~* Use of antiemetic in the previous week.~* Regular use of opioids.~* Hepatic dysfunction.~* Confirmed renal impairment. Diabetes mellitus Cognitive dysfunction Conversion to laparotomy during gynecologic laparoscopy.

- Gender: FEMALE
- Minimum Age: 29 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- TEAS Group (Type: OTHER): TEAS consisted of 30 min of stimulation (12-15 mA, 2/100 Hz) at the Hegu (L14) and Neiguan (PC6) before anesthesia. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
- Con Group (Type: OTHER): The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 19-64 years old~* Informed consent form has been signed and dated~* Able to comply with the requirements of the study~Exclusion Criteria:~* Known systemic hypersensitive to eggs, chicken proteins, or any of the vaccine components~* Personal history of Guillain-Barre syndrome(GBS)~* Subjects with severe chronic disease who are considered by investigator to be ineligible for the study~* Subjects who received a vaccination within 28 days before enrollment or who are scheduled for another vaccination during the study~* Immunocompromised subjects with immunodeficiency disease or subjects receiving immunosuppressive or immunomodulating therapy~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- GC3114 (Type: EXPERIMENTAL): Pre-filled syringe inj., 0.5ml, Once, IM
- GCFLU Quadrivalent (Type: ACTIVE_COMPARATOR): Pre-filled syringe inj., 0.5ml, Once, IM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Health Literacy and Oral Education

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women~* To be literate~* Pregnancy maximum in the 32nd week~Exclusion Criteria:~* Physical or mental disability

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Standardized oral instruction (Type: EXPERIMENTAL): 60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
- Written form instruction (Type: EXPERIMENTAL): 60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
- Control (Type: EXPERIMENTAL): 60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete